Clinical Research Informer

J&J builds case for antidepressant Spravato with head-to-head trial

pharmaphorum

NOVEMBER 24, 2022

Johnson & Johnson’s Spravato therapy for treatment-resistant depression (TRD) hasn’t made the impact the company hoped for in the market, and it is looking to new clinical results to accelerate its take-up. The post J&J builds case for antidepressant Spravato with head-to-head trial appeared first on.

Trials

Trials Sales Drugs Marketing

Axsome bounces back as FDA clears depression drug

pharmaphorum

AUGUST 21, 2022

That status goes to Johnson & Johnson’s Spravato (esketamine), which was approved in March 2019 and is administered as a nasal spray twice a week for four weeks. Auvelity isn’t the first NMDA-targeting antidepressant to reach the market.

Drugs

Drugs FDA Approval Production Marketing

J&J builds case for antidepressant Spravato with head-to-head trial

Axsome bounces back as FDA clears depression drug

Stay Connected